Caribou Biosciences (NASDAQ: CRBU) trims Q1 loss, holds $118.6M cash
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Caribou Biosciences reported first quarter 2026 results and highlighted key progress in its allogeneic CAR-T programs. Licensing and other third-party revenue was $2.4 million for the three months ended March 31, 2026, essentially unchanged from $2.4 million a year earlier.
Research and development expenses fell to $20.6 million from $35.5 million, and general and administrative expenses declined to $8.1 million from $9.7 million, reflecting prior workforce reductions and pipeline prioritization. Net loss narrowed to $25.1 million, or $0.26 per share, compared with a $40.0 million loss, or $0.43 per share, in 2025.
Caribou ended the quarter with $118.6 million in cash, cash equivalents, and marketable securities and expects this to fund its current operating plan, including CB-011 dose expansion and start-up activities for the planned pivotal vispa-cel trial, into the second half of 2027. The company also reported FDA alignment on the pivotal ANTLER-3 phase 3 design for vispa-cel and RMAT designation for CB-011 based on promising phase 1 data.
Positive
- None.
Negative
- None.
Insights
Caribou cut expenses, extended cash runway, and advanced pivotal-ready CAR-T programs.
Caribou Biosciences posted Q1 2026 licensing revenue of $2.4 million, roughly flat year over year, while significantly reducing operating costs. R&D dropped to $20.6 million from $35.5 million, and G&A declined to $8.1 million from $9.7 million, narrowing net loss to $25.1 million.
Cash, cash equivalents, and marketable securities were $118.6 million as of March 31, 2026. Management states this should fund the current plan, including CB-011 dose expansion and vispa-cel pivotal start-up activities, into 2H 2027, with additional funding options under exploration for the full vispa-cel phase 3 trial.
On the clinical side, Caribou reached FDA alignment on the pivotal ANTLER-3 phase 3 design for vispa-cel in second-line LBCL and received RMAT designation for CB-011 in relapsed or refractory multiple myeloma, based on a 92% overall response rate and 75% complete or stringent complete responses in an initial 12-patient cohort.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Licensing and third-party revenue: $2.4M
Research and development expense: $20.6M
General and administrative expense: $8.1M
+5 more
8 metrics
Licensing and third-party revenue
$2.4M
Three months ended March 31, 2026 vs. $2.4M in 2025
Research and development expense
$20.6M
Q1 2026 vs. $35.5M in Q1 2025
General and administrative expense
$8.1M
Q1 2026 vs. $9.7M in Q1 2025
Net loss
$25.1M
Q1 2026 vs. $40.0M in Q1 2025
Net loss per share
$0.26
Basic and diluted in Q1 2026 vs. $0.43 in 2025
Cash, equivalents, and marketable securities
$118.6M
As of March 31, 2026 vs. $142.8M at December 31, 2025
Total assets
$149.0M
As of March 31, 2026 vs. $175.4M at December 31, 2025
Weighted-average shares
95,861,716
Basic and diluted Q1 2026 vs. 92,679,493 in Q1 2025
Key Terms
Regenerative Medicine Advanced Therapy (RMAT) designation, progression-free survival, allogeneic CAR-T cell therapy, minimal residual disease negativity, +2 more
6 terms
Regenerative Medicine Advanced Therapy (RMAT) designation regulatory
"the FDA granted RMAT designation to CB-011 for r/r MM"
A Regenerative Medicine Advanced Therapy (RMAT) designation is a U.S. regulatory status given to certain cell, gene, or tissue-based treatments that show promise for serious conditions and early clinical evidence of benefit. It signals that regulators will provide extra guidance and expedited review steps—like giving a promising project a “fast pass” through some development checkpoints—which can shorten time to market and reduce regulatory risk, making the program more valuable and noteworthy to investors.
progression-free survival medical
"The primary endpoint is progression-free survival (PFS)."
Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
allogeneic CAR-T cell therapy medical
"vispa-cel is an allogeneic anti-CD19 CAR-T cell therapy"
A therapy in which immune cells taken from a healthy donor are genetically reprogrammed to recognize and kill cancer cells and then given to a patient; think of it as an off‑the‑shelf, engineered immune weapon rather than one made from the patient’s own tissue. It matters to investors because this approach can be faster and cheaper to manufacture at scale than patient‑specific therapies, but carries additional risks such as immune rejection, regulatory hurdles and complex manufacturing that affect clinical success, costs and commercial potential.
minimal residual disease negativity medical
"91% minimal residual disease negativity."
lymphodepletion regimen medical
"preceded by a lymphodepletion (LD) regimen of cyclophosphamide"
orphan drug designations regulatory
"The FDA granted CB-011 Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations"
A regulatory status granted to medicines that treat rare diseases, giving developers special incentives and protections — for example, reduced fees, tax benefits, and a period of exclusive marketing once approved. Think of it as a government “boost” that lowers development costs and shields a product from direct competition for a time; investors watch for it because it can raise a drug’s commercial value and reduce the financial risk of bringing a treatment for a small patient group to market.
Earnings Snapshot
Licensing and other third-party revenue: $2.4M · Guidance included
Three months ended March 31, 2026
Licensing and other third-party revenue
$2.4M
slightly up from $2.4M in Q1 2025
Net loss
$25.1M
improved from $40.0M in Q1 2025
R&D expense
$20.6M
down from $35.5M in Q1 2025
Guidance
Caribou expects existing cash, cash equivalents, and marketable securities to fund its current operating plan into the second half of 2027.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________
FORM 8-K
________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2026
________________________________________
(Exact name of Registrant as Specified in Its Charter)
________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s Telephone Number, Including Area Code: (510 ) 982-6030
N/A
(Former Name or Former Address, if Changed Since Last Report)
________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 7, 2026, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026, and providing a business update. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in any such filing, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press Release Issued by Caribou Biosciences, Inc. on May 7, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Caribou Biosciences, Inc. | |||||||||||
| Date: | May 7, 2026 | By: | /s/ Rachel E. Haurwitz | ||||||||
Rachel E. Haurwitz, Ph.D. President and Chief Executive Officer | |||||||||||
Exhibit 99.1
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL --
-- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 --
-- CaMMouflage phase 1 trial evaluating CB-011 continues to enroll r/r MM patients, dose escalation and expansion clinical data updates expected in 2026 --
BERKELEY, Calif., May 7, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter of 2026 and provided a business update.
“We are pleased to have aligned with the FDA on the pivotal ANTLER-3 trial design for vispa-cel,” said Rachel Haurwitz, PhD, president and CEO of Caribou. “Vispa-cel continues to demonstrate a differentiated profile as an off-the-shelf CAR-T cell therapy with a well-tolerated safety profile and robust response rates resulting in long-term durable outcomes in high-risk patients. Our pivotal trial will compare vispa-cel to standard-of-care regimens that lack curative intent yet are often the only options available to the 75% of second-line large B cell lymphoma patients who do not receive autologous CAR-T cell therapy. We look forward to reporting longer follow up on the phase 1 data for vispa-cel at an upcoming medical conference this year as well as sharing longer follow up on dose escalation and initial dose expansion data for CB-011 in patients with relapsed or refractory multiple myeloma in 2026.”
Clinical highlights
Vispacabtagene regedleucel (vispa-cel; formerly CB-010), a clinical-stage allogeneic anti-CD19 CAR-T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphoma
•Caribou reached alignment with the U.S. Food and Drug Administration (FDA) regarding the vispa-cel pivotal trial design following interactions to date with the agency enabled by the Regenerative Medicine Advanced Therapy (RMAT) designation for vispa-cel.
•ANTLER-3 is expected to be a randomized, controlled pivotal phase 3 clinical trial enrolling approximately 250 CD19-naïve second-line (2L) large B cell lymphoma (LBCL) patients who are not eligible for transplant and not candidates or not eligible for autologous CAR-T cell therapy based on access challenges or medical criteria, including the need for urgent therapy.
◦Patients in the investigational arm will receive a single dose of 80x106 vispa-cel CAR-T cells following lymphodepletion.
◦Patients in the comparator arm will be treated with an investigator’s choice of standard-of-care regimen, such as: polatuzumab vedotin (Pola), bendamustine, rituximab (R) (Pola-BR); R, gemcitabine, and oxaliplatin (R-GemOx); Pola-R-GemOx (Pola-RGO); or tafasitamab and lenalidomide. Crossover to the vispa-cel arm is permitted after progressive disease.
◦The primary endpoint is progression-free survival (PFS).
◦Clinical trial sites will include both academic and sophisticated community centers in the United States and globally.
1
•Clinical data disclosed in November 2025 and in a poster presented at the 2026 Tandem Meetings highlight vispa-cel’s potential — as an immediately available, off-the-shelf CAR-T cell therapy manufactured at scale — to help meet the needs of the 75% of 2L LBCL patients who do not receive autologous CAR-T cell therapy.
•Longer follow up ANTLER phase 1 clinical trial data will be presented at a medical conference in 2026.
CB-011, a clinical-stage allogeneic anti-BCMA CAR-T cell therapy for patients with relapsed or refractory multiple myeloma (r/r MM)
•On March 31, 2026, Caribou announced the FDA granted RMAT designation to CB-011 for r/r MM.
•RMAT was granted based on promising initial clinical data, including previously disclosed data on the 12-patient, BCMA-naïve r/r MM patient cohort treated at the recommended dose for expansion: 92% overall response rate, 75% complete response (CR) or stringent CR rate, and 91% minimal residual disease negativity. These data highlight CB-011’s potential as the best-in-class allogeneic CAR-T cell therapy for patients with r/r MM.
•Caribou is enrolling BCMA-naïve and prior BCMA therapy-exposed r/r MM patients in the dose expansion portion of the CaMMouflage trial and expects to report longer follow up on dose escalation data and initial dose expansion data in 2026.
Upcoming events
•BofA Securities 2026 Health Care Conference, Las Vegas, NV
May 13, 2026, fireside chat at 8:40 am PT
Webcast
First quarter 2026 financial results
Licensing and other third-party revenue: Revenue from licensing and other third-party agreements was $2.4 million for the three months ended March 31, 2026, unchanged from the same period in 2025.
R&D expenses: Research and development expenses were $20.6 million for the three months ended March 31, 2026, compared to $35.5 million for the same period in 2025. The decrease was primarily related to decreased external contract manufacturing organization and contract research organization activities, expenses related to the reduction in workforce and strategic pipeline prioritization announced in April 2025, facilities and allocated expenses, and expenses related to licenses, sublicensing revenue, and milestones.
G&A expenses: General and administrative expenses were $8.1 million for the three months ended March 31, 2026, compared to $9.7 million for the same period in 2025. The decrease was primarily due to personnel-related expenses related to the reduction in workforce and strategic pipeline prioritization announced in April 2025 and lower legal expenses.
Cash, cash equivalents, and marketable securities: Caribou had $118.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026, compared to $142.8 million as of December 31, 2025. Caribou expects its cash, cash equivalents, and marketable securities will be sufficient to fund its current operating plan, including dose expansion for CB-011 and certain start-up
2
activities for its planned vispa-cel pivotal trial, into 2H 2027. The Company is exploring multiple options to fully fund its planned vispa-cel pivotal trial.
About vispacabtagene regedleucel
Vispacabtagene regedleucel (vispa-cel; formerly known as CB-010) is an allogeneic anti-CD19 CAR-T cell therapy evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). To Caribou’s knowledge, vispa-cel is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to enhance CAR-T cell activity by limiting premature CAR-T cell exhaustion. The FDA granted vispa-cel Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations for B-NHL.
About the ANTLER phase 1 clinical trial
The ANTLER phase 1 clinical trial evaluated vispa-cel in adult patients with r/r B-NHL in a multicenter, open-label trial. As of a September 2, 2025, data cutoff date, 84 patients were treated in the trial. Using a 3+3 enrollment strategy, safety and efficacy were assessed in 16 patients in dose escalation who received a single dose of 40x106, 80x106, and 120x106 CAR-T cell CAR-T cells preceded by a lymphodepletion (LD) regimen of cyclophosphamide at 60 mg/kg/day for 2 days followed by fludarabine at 25 mg/m2/day for 5 days. Eighty million (80x106) CAR-T cells was selected as the recommended phase 2 dose (RP2D). Sixty-three second-line large B cell lymphoma (2L LBCL) patients received a single dose of vispa-cel during dose expansion. Five patients were enrolled in a cohort of third-line or later LBCL patients with prior exposure to CD19-targeted therapy. Additional information on the ANTLER trial (NCT04637763) can be found at www.clinicaltrials.gov.
About CB-011
CB-011 is an allogeneic anti-BCMA CAR-T cell therapy being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM). To Caribou’s knowledge, CB-011 is the first allogeneic CAR-T cell therapy in the clinic that is engineered to enable activity through an immune cloaking strategy with a B2M knockout and insertion of a B2M–HLA-E fusion protein to blunt immune-mediated rejection. The FDA granted CB-011 Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations for r/r MM.
About the CaMMouflage phase 1 clinical trial
The CaMMouflage clinical trial is a multicenter, open-label phase 1 trial evaluating CB-011 in adults with r/r MM who have been treated with three or more prior lines of therapy. Using a 3+3 dose escalation design, safety and efficacy of CB-011 were evaluated in 48 patients at multiple dose levels and two different lymphodepletion (LD) regimens. Thirteen patients were treated with a single dose of CB-011 (50x106 [N=3], 150x106 [N=7], and 450x106 [N=3] CAR-T cells) with an LD regimen of 300 mg/m2 cyclophosphamide and 30 mg/m2 fludarabine daily for 3 days, and 35 patients were treated with a single dose of CB-011 (150x106 [N=6], 300x106 [N=13], 450x106 [N=13], and 800x106 [N=3] CAR-T cells) with an LD regimen of 500 mg/m2 cyclophosphamide and 30 mg/m2 fludarabine daily for 3 days. The dose expansion portion of the trial is evaluating safety and efficacy of CB-011 at 450x106 CAR-T cells with the selected LD of 500 mg/m2 cyclophosphamide and 30 mg/m2 fludarabine daily for three days. Additional information on the CaMMouflage trial (NCT05722418) can be found at www.clinicaltrials.gov.
About Caribou Biosciences, Inc.
3
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou’s chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the company @CaribouBio and visit www.cariboubio.com.
Forward-looking statements and important information
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “likely,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, any statements regarding the initiation, timing, progress, strategy, plans, objectives, and expectations (including as to the results) with respect to the company’s CAR-T cell therapy product candidate clinical trials, including the expected trial design of the pivotal phase 3 clinical trial for vispa-cel in 2L LBCL CD19-naïve patients and efforts to secure funding this pivotal trial; the expected release of longer follow up data on ANTLER phase 1 clinical trial data at an upcoming medical conference this year; reporting longer follow-up on dose escalation and initial dose expansion data in 2026 from the company’s ongoing CaMMouflage phase 1 clinical trial for CB-011 in patients with r/r MM; the company’s ability to successfully develop the company’s CAR-T cell therapy product candidates and to obtain and maintain regulatory approval for these product candidates; the likelihood of the company’s clinical trials demonstrating safety and efficacy of the company’s CAR-T cell therapy product candidates; the beneficial characteristics, safety, efficacy, therapeutic effects, and potential advantages of the company’s CAR-T cell therapy product candidates; the expected timing or likelihood of regulatory filings and approval for the company’s CAR-T cell therapy product candidates; and the expected runway of cash, cash equivalents, and marketable securities. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include, without limitation, risks inherent in the development of allogeneic CAR-T cell therapy products; uncertainties related to the initiation, cost, timing, progress, and results of the company’s current and future clinical trials; the risk that initial, preliminary, or interim clinical trial data will not ultimately be predictive of the safety and efficacy of the company’s CAR-T cell therapy product candidates or that clinical outcomes may differ as patient enrollment continues and as more patient data becomes available; the risk that different conclusions or considerations are reached once additional data have been received and fully evaluated; the ability to obtain key regulatory input and approvals; and risks related to the company’s limited operating history, history of net operating losses, financial position, and the company’s ability to raise additional capital as needed to fund the company’s operations and CAR-T cell therapy product candidate development, including the ability to fully fund the company’s pivotal phase 3 clinical trial for vispa-cel; as well as other risk factors described from time to time in Caribou’s filings with the Securities and Exchange Commission (SEC), including the company’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Except as
4
required by law, Caribou undertakes no obligation to update publicly any forward-looking statements for any reason.
5
Caribou Biosciences, Inc.
Condensed Consolidated Balance Sheet Data
(in thousands)
(unaudited)
| March 31, 2026 | December 31, 2025 | ||||||||||
| Cash, cash equivalents, and marketable securities | $ | 118,627 | $ | 142,845 | |||||||
| Total assets | 148,998 | 175,367 | |||||||||
| Total liabilities | 46,980 | 53,192 | |||||||||
| Total stockholders’ equity | 102,018 | 122,175 | |||||||||
| Total liabilities and stockholders' equity | $ | 148,998 | $ | 175,367 | |||||||
6
Caribou Biosciences, Inc.
Condensed Consolidated Statement of Operations
(in thousands, except share and per share data)
(unaudited)
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Licensing and other third-party revenue | $ | 2,397 | $ | 2,353 | |||||||
| Operating expenses: | |||||||||||
| Research and development | 20,611 | 35,531 | |||||||||
| General and administrative | 8,066 | 9,735 | |||||||||
| Total operating expenses | 28,677 | 45,266 | |||||||||
| Loss from operations | (26,280) | (42,913) | |||||||||
| Other income | |||||||||||
| Other income, net | 1,195 | 2,922 | |||||||||
| Total other income | 1,195 | 2,922 | |||||||||
| Net loss | (25,085) | (39,991) | |||||||||
| Other comprehensive loss | |||||||||||
| Net unrealized loss on available-for-sale marketable securities, net of tax | (126) | (88) | |||||||||
| Net comprehensive loss | $ | (25,211) | $ | (40,079) | |||||||
| Net loss per share, basic and diluted | $ | (0.26) | $ | (0.43) | |||||||
| Weighted-average common shares outstanding, basic and diluted | 95,861,716 | 92,679,493 | |||||||||
7
Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
investor.relations@cariboubio.com
media@cariboubio.com
8
FAQ
How did Caribou Biosciences (CRBU) perform financially in Q1 2026?
Caribou Biosciences reported Q1 2026 licensing and other revenue of $2.4 million, roughly flat year over year. Net loss improved to $25.1 million, or $0.26 per share, compared with a $40.0 million loss, or $0.43 per share, in the same period of 2025.
What were Caribou Biosciences (CRBU) research and development costs in Q1 2026?
Research and development expenses were $20.6 million for the three months ended March 31, 2026, down from $35.5 million in 2025. The company attributed the decrease mainly to reduced contract manufacturing and research activities and savings from an April 2025 workforce reduction and pipeline prioritization.
How much cash does Caribou Biosciences (CRBU) have and how long will it last?
Caribou held $118.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026, down from $142.8 million at year-end 2025. Management expects this balance to fund its current operating plan into the second half of 2027, including CB-011 dose expansion and vispa-cel trial start-up activities.
What is the status of Caribou Biosciences’ vispa-cel ANTLER-3 pivotal trial?
Caribou reached alignment with the FDA on the pivotal ANTLER-3 phase 3 trial design for vispa-cel in second-line large B cell lymphoma. The randomized trial is expected to enroll about 250 CD19-naïve patients, comparing a single 80×10^6-cell vispa-cel dose against standard-of-care regimens with progression-free survival as the primary endpoint.
What clinical results support Caribou Biosciences’ CB-011 CAR-T program?
CB-011 received FDA RMAT designation for relapsed or refractory multiple myeloma based on initial data from 12 BCMA-naïve patients at the expansion dose. In that cohort, CB-011 achieved a 92% overall response rate, 75% complete or stringent complete responses, and 91% minimal residual disease negativity, supporting continued development.
What upcoming data and events has Caribou Biosciences (CRBU) guided for 2026?
Caribou expects to present longer follow-up ANTLER phase 1 data for vispa-cel at a 2026 medical conference. The company also plans to report longer follow-up dose-escalation data and initial dose-expansion data from the CaMMouflage phase 1 trial of CB-011 during 2026, and to participate in the BofA Securities 2026 Health Care Conference.